BCL2 and cancer: Clinically, the B-cell lymphoma 2 (Bcl-2) specific inhibitor venetoclax has been proven to be an excellent novel target for cancer treatment. Research on venetoclax is continuing with nearly 200 randomized controlled trials (RCTs) planned. These will eventually show the cancers that are more susceptible and the kind of resistance that may appear.